Fourth Department of Orthopedics, Cangzhou Central Hospital, Cangzhou, China.
Department of Pharmacy, Cangzhou Central Hospital, Cangzhou, China.
J Interferon Cytokine Res. 2023 Aug;43(8):335-343. doi: 10.1089/jir.2023.0083.
Osteosarcoma is the most prevalent type of primary bone malignancy in children and adolescents. The effect of cytokines on osteosarcoma prognosis has been studied and reported. This meta-analysis aimed to assess the prognostic value of cytokines as osteosarcoma biomarkers. Databases including PubMed, Embase, and Cochrane Library were searched for studies on the prognostic value of cytokines in osteosarcoma. From the eligible studies, data on overall survival (OS), disease-free survival, and metastasis-free survival (MFS) were extracted. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. A total of 11 studies involving 755 patients were included in this analysis. High macrophage migration inhibitory factor (MIF) expression in tumors was significantly associated with shortened OS (HR = 2.01, 95% CI: 1.18-3.42, = 0.010) and MFS (HR = 2.51, 95% CI: 1.47-4.01, = 0.001). Elevated T cell immunoglobulin and mucin domain-3 (Tim-3) levels in serum correlated with increased risk of disease progression in patients with osteosarcoma (HR = 3.14, 95% CI: 2.88-3.03, 0.001). However, interleukin 6 (IL-6) and tumor necrosis factor were not substantially associated with osteosarcoma prognosis. Owing to a paucity of research, other relevant cytokines [interferon-α/β receptor, tissue factor, macrophage inhibitory cytokine 1 (MIC-1), and IL-23] could not be combined. In conclusion, MIF levels in tumors and Tim-3 levels in serum can be potential biomarkers of poor prognosis in osteosarcoma. To confirm this finding and implement these biomarkers into clinical applications, additional large-scale, high-quality studies are needed.
骨肉瘤是儿童和青少年中最常见的原发性骨恶性肿瘤。已经研究并报道了细胞因子对骨肉瘤预后的影响。本荟萃分析旨在评估细胞因子作为骨肉瘤生物标志物的预后价值。检索了包括 PubMed、Embase 和 Cochrane Library 在内的数据库，以查找细胞因子在骨肉瘤预后中的研究。从合格的研究中提取了总生存（OS）、无病生存和无转移生存（MFS）的数据。计算了合并的风险比（HR）和 95%置信区间（CI）。这项分析共纳入了 11 项涉及 755 名患者的研究。肿瘤中高迁移率族蛋白 B1（MIF）表达与 OS 缩短显著相关（HR=2.01，95%CI：1.18-3.42，P=0.010）和 MFS（HR=2.51，95%CI：1.47-4.01，P=0.001）。血清中 T 细胞免疫球蛋白和粘蛋白结构域 3（Tim-3）水平升高与骨肉瘤患者疾病进展风险增加相关（HR=3.14，95%CI：2.88-3.03，P<0.001）。然而，白细胞介素 6（IL-6）和肿瘤坏死因子与骨肉瘤预后无显著相关性。由于研究较少，其他相关细胞因子[干扰素-α/β受体、组织因子、巨噬细胞抑制因子 1（MIC-1）和 IL-23]无法进行合并。总之，肿瘤中 MIF 水平和血清中 Tim-3 水平可能是骨肉瘤不良预后的潜在生物标志物。为了证实这一发现并将这些生物标志物应用于临床，还需要进行更多的大规模、高质量的研究。
